Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Game Changer

Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Glorious Success Limited in Reverse Takeover Transaction

Biocure’s reverse takeover rescues cash-strapped shell with Korean MMA venture, but leaves existing holders owning just 8%

By The Northwire Desk — AI Analysis Jun 22, 2026 · 21:40 CURE · 0.015 Biocure Technology Inc.
Executive Summary
  • Biocure Technology entered a binding letter agreement for a reverse takeover of Glorious Success Limited (GSL), a Hong Kong holding company that controls South Korea’s Black Combat MMA promotion.
  • The transaction includes a ~16.42:1 share consolidation, a minimum CAD$3.09M private placement at $2.20/share, and debt settlements totaling ~$2.71M.
  • Existing CURE shareholders would hold only 8.1% of the resulting issuer, while GSL’s sellers, private placement subscribers, and bonus-share recipients take ~91.9%.
  • A definitive agreement must be signed by September 15, 2026, and the deal is conditional on due diligence, shareholder and regulatory approvals, and completion of the consolidation, placement, and debt settlements.
  • GSL had US$4.59M in assets, US$4.24M in liabilities, and US$2.83M in revenue at end‑2025; ~US$1.73M of liabilities will be converted to shares.
  • Upon closing, the board will be reconstituted with a majority of GSL nominees, the CEO will be chosen by GSL, and the company will change its name and CSE symbol.
Material Impact
  • The news is a lifeline for a pre‑revenue shell that was explicitly at risk of going concern. The reverse takeover completely changes the fundamental character of the company, from a dormant life‑sciences shell with a $23.9M accumulated deficit into an operating sports‑media business.
  • However, the transaction is extremely dilutive for existing shareholders: they will own just 8.1% of the post‑deal entity. The value they retain hinges entirely on the success of the Black Combat business, which generated only US$2.83M in revenue with a thin asset‑liability balance at the end of 2025.
  • The deal is a “game changer” in the sense that it prevents the likely collapse of the shell and provides a new business line, but it transfers almost all economic value to the incoming GSL stakeholders and new investors. For current shareholders, the outcome is less a windfall than a low‑probability option on a turnaround.
  • The binding letter agreement still contains significant closing risk: due diligence, a definitive agreement by mid‑September, a minimum $3.09M placement, and multiple regulatory/ shareholder approvals. Failure would leave Biocure right back in its working‑capital‑deficient, going‑concern‑warned state.
  • The lack of pro‑forma combined financials or detailed revenue breakdown for Black Combat limits confidence in the standalone quality of the sports‑media asset.
CURE · Price
Company Overview
  • Prior-period context (from FY2025 annual filing): Biocure Technology Inc. was essentially a non‑operating shell. It reported no revenue, a net loss of $102,861, and had an accumulated deficit of $23.9 million. The company had only $41,425 in cash against a working capital deficiency of $389,541 and total assets of $2.01M (mostly a 45% investment in Korea Waterbury Uranium Limited Partnership valued at $1.97M). The previous reverse takeover attempt with Atriva Therapeutics was terminated in July 2024. Management’s MD&A flagged going‑concern doubt and stated the company’s survival depended on raising new financing.
  • The planned RTO would turn this shell into a sports‑media promoter through GSL’s Black Combat business, effectively leaving Biocure’s legacy assets sidelined.
Read the original news release →